Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity - PubMed (original) (raw)
. 2008 Jun;115(6):1065-1070.e1.
doi: 10.1016/j.ophtha.2007.08.050. Epub 2007 Nov 26.
Affiliations
- PMID: 18031819
- DOI: 10.1016/j.ophtha.2007.08.050
Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity
Kenan Sonmez et al. Ophthalmology. 2008 Jun.
Abstract
Purpose: To understand better the role of vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1alpha (SDF-1alpha) in the pathogenesis of retinopathy of prematurity (ROP).
Design: Experimental study.
Participants: The study group consisted of 22 eyes with stage 4 ROP (12 vascularly active, 10 vascularly inactive), from which vitreous samples were obtained. Vitreous samples from 5 eyes undergoing surgery for congenital cataract were used as controls.
Methods: The vitreous samples were analyzed for concentrations of total protein, VEGF, and SDF-1alpha. Vascular activity was graded at the time of surgery and was defined as the presence of plus disease, neovascularization growing onto the vitreous at the ridge or tractional detachment area, or combined effusive and tractional retinal detachment.
Main outcome measures: Vitreous concentrations of VEGF and SDF-1alpha were compared among vascularly active stage 4 ROP eyes, vascularly inactive stage 4 ROP eyes, and control eyes.
Results: Vitreous concentrations of VEGF and SDF-1alpha were elevated in eyes with ROP compared with control eyes. The median VEGF level was 59 pg/ml (range, 38-135 pg/ml) in the control group, 316 pg/ml (range, 105-665 pg/ml) in the vascularly inactive ROP group, and 3454 pg/ml (range, 774-8882 pg/ml) in the vascularly active ROP group. The median SDF-1alpha level was 327 pg/ml (range, 299-393 pg/ml) in the control group, 609 pg/ml (range, 515-1116 pg/ml) in the vascularly inactive ROP group, and 1029 pg/ml (range, 807-3015 pg/ml) in the vascularly active ROP group. The differences in both vitreous VEGF and SDF-1alpha concentrations between the three groups were statistically significant (P<0.001 and P<0.001, respectively). The eyes graded as vascularly active at the time of surgery demonstrated the highest vitreous levels of both VEGF and SDF-1alpha, and these levels were statistically significant when compared with vascularly inactive eyes (P<0.001 and P = 0.001, respectively) and control eyes (P = 0.001 and P = 0.001, respectively).
Conclusions: These findings confirm the increase in vitreous VEGF and SDF-1alpha levels in eyes with vascularly active stage 4 ROP. Anti-VEGF treatment may be of benefit in some eyes that develop ROP.
Similar articles
- Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.
Sato T, Kusaka S, Shimojo H, Fujikado T. Sato T, et al. Ophthalmology. 2009 Nov;116(11):2165-9. doi: 10.1016/j.ophtha.2009.04.026. Epub 2009 Aug 22. Ophthalmology. 2009. PMID: 19700197 - Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T. Arimura N, et al. Ophthalmology. 2009 May;116(5):921-6. doi: 10.1016/j.ophtha.2008.12.024. Ophthalmology. 2009. PMID: 19410951 - Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
Sato T, Kusaka S, Shimojo H, Fujikado T. Sato T, et al. Ophthalmology. 2009 Sep;116(9):1599-603. doi: 10.1016/j.ophtha.2008.12.023. Epub 2009 Apr 15. Ophthalmology. 2009. PMID: 19371954 - Pathogenesis of retinopathy of prematurity.
Smith LE. Smith LE. Growth Horm IGF Res. 2004 Jun;14 Suppl A:S140-4. doi: 10.1016/j.ghir.2004.03.030. Growth Horm IGF Res. 2004. PMID: 15135797 Review.
Cited by
- Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
Nicoară SD, Ștefănuţ AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC. Nicoară SD, et al. Med Sci Monit. 2016 Apr 10;22:1192-209. doi: 10.12659/msm.897095. Med Sci Monit. 2016. PMID: 27062023 Free PMC article. - Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity.
Budd SJ, Thompson H, Hartnett ME. Budd SJ, et al. Arch Ophthalmol. 2010 Aug;128(8):1014-21. doi: 10.1001/archophthalmol.2010.158. Arch Ophthalmol. 2010. PMID: 20697002 Free PMC article. - Reply: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
Mintz-Hittner HA. Mintz-Hittner HA. Retina. 2009 Apr;29(4):562-4. doi: 10.1097/iae.0b013e31819a98b9. Retina. 2009. PMID: 26281628 Free PMC article. No abstract available. - Screening and Treatment in Retinopathy of Prematurity.
Stahl A, Göpel W. Stahl A, et al. Dtsch Arztebl Int. 2015 Oct 23;112(43):730-5. doi: 10.3238/arztebl.2015.0730. Dtsch Arztebl Int. 2015. PMID: 26568177 Free PMC article. Review. - Tear Fluid Angiogenic Factors: Potential Noninvasive Biomarkers for Retinopathy of Prematurity Screening in Preterm Infants.
Vinekar A, Nair AP, Sinha S, Vaidya T, Chakrabarty K, Shetty R, Ghosh A, Sethu S. Vinekar A, et al. Invest Ophthalmol Vis Sci. 2021 Mar 1;62(3):2. doi: 10.1167/iovs.62.3.2. Invest Ophthalmol Vis Sci. 2021. PMID: 33646290 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources